OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies
Eric L. Simpson, Robert Bissonnette, Zelma C. Chiesa Fuxench, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 3
Eric L. Simpson, Robert Bissonnette, Zelma C. Chiesa Fuxench, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 3
Showing 3 citing articles:
Ruxolitinib cream monotherapy for facial and/or neck atopic dermatitis: results from a decentralized, randomized phase 2 clinical trial
Zelma C. Chiesa Fuxench, Zhihong Lai, Yutzu Kuo, et al.
Journal of Dermatological Treatment (2025) Vol. 36, Iss. 1
Open Access | Times Cited: 1
Zelma C. Chiesa Fuxench, Zhihong Lai, Yutzu Kuo, et al.
Journal of Dermatological Treatment (2025) Vol. 36, Iss. 1
Open Access | Times Cited: 1
Fungal Head and Neck Dermatitis: Current Understanding and Management
Albert C. Chong, F.J. Navarro‐Triviño, Malcolm Su, et al.
Clinical Reviews in Allergy & Immunology (2024) Vol. 66, Iss. 3, pp. 363-375
Open Access | Times Cited: 4
Albert C. Chong, F.J. Navarro‐Triviño, Malcolm Su, et al.
Clinical Reviews in Allergy & Immunology (2024) Vol. 66, Iss. 3, pp. 363-375
Open Access | Times Cited: 4
Adverse event of ruxolitinib cream: a real-world analysis based on FDA adverse event reporting system from 2021 to 2024
Shi Zhou, Lei Li, Ling Jiang, et al.
Expert Opinion on Drug Safety (2024)
Closed Access
Shi Zhou, Lei Li, Ling Jiang, et al.
Expert Opinion on Drug Safety (2024)
Closed Access
